The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014)

BMC Cancer
Shahin De LaraAnikó Kovács

Abstract

Current prognostic markers cannot adequately predict the clinical outcome of breast cancer patients. Therefore, additional biomarkers need to be included in routine immune panels. FOXA1 was a significant predictor of favorable outcome in primary breast cancer, while Nestin expression is preferentially found in triple-negative tumors with increased rate of nodal metastases, and reduced survival. No studies have investigated the prognostic value of FOXA1 and Nestin expression in breast cancer metastases. Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression. Cox regression analysis assessed the prognostic value of FOXA1 and Nestin expression. In breast cancer metastases, FOXA1 expression was associated with Nestin-negativity, GATA3-positivity, ER-positivity, HER2-positivity and non-triple-negative status (P < 0.05). In contrast, Nestin expression was associated with FOXA1-negative, GATA3-negative, ER-negative, and triple-negative metastases (P < 0.05). Univariate Cox regression analysis showed FOXA1 expression was predictive of overall survival (OS, P = 0.00048) and metastasis-free survival (DMFS, P = 0.0011), as well as, dista...Continue Reading

References

Jun 10, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hany Onsy HabashyIan O Ellis
Jul 22, 2008·Journal of Clinical Pathology·S ParryJ S Reis-Filho
Mar 6, 2009·Expert Reviews in Molecular Medicine·Harikrishna Nakshatri, Sunil Badve
Jun 25, 2009·Breast Cancer Research : BCR·André AlbergariaFernando Schmitt
Dec 1, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Foluso O AdemuyiwaSunil Badve
Apr 20, 2011·Breast Cancer Research and Treatment·Rutika J MehtaSunil Badve
Sep 22, 2011·The EMBO Journal·Michael A AugelloKaren E Knudsen
May 23, 2012·Nature Genetics·Christopher E BarbieriLevi A Garraway
Jun 23, 2012·Nature·Catherine S GrassoScott A Tomlins
Feb 20, 2013·Frontiers in Oncology·Jessica L L RobinsonJason S Carroll
Jun 19, 2013·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Mai KawaseHiroko Yamashita
Jan 15, 2014·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yuichi HisamatsuYoshihiko Maehara
Feb 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Qing HuJin-Hai Tang
Apr 2, 2016·Science Advances·Gaihua ZhangZhaoyu Li
Feb 13, 2017·Biochemical and Biophysical Research Communications·Wen FengChunhui Song
Jun 29, 2017·International Journal of Oncology·Aleksandra NowakPiotr Dziegiel
Sep 5, 2017·Biological & Pharmaceutical Bulletin·Erina AnzaiNoritaka Yamaguchi
Nov 22, 2017·Breast Cancer Research and Treatment·Karama AslehTorsten O Nielsen

❮ Previous
Next ❯

Software Mentioned

R
R stats
Bioconductor
forestplot
survminer

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.